Impact of Salpingectomy on Ovarian Reserve (NCT02284711) | Clinical Trial Compass
CompletedNot Applicable
Impact of Salpingectomy on Ovarian Reserve
France96 participantsStarted 2015-03-09
Plain-language summary
Epithelial cancer of the ovaries is the most severe form of gynecologic cancer; a significant proportion of ovarian cancers originate from the Fallopian tube. Guidelines therefore now recommend systematically associating prophylactic salpingectomy to benign hysterectomy. The principal objective of the present study is to assess the impact of salpingectomy on ovarian reserve by anti-Müllerian hormone (AMH) assay and calculating the Doppler index of vascular resistance in the ovarian vessels. The secondary objective is to compare ovarian reserve results between two coagulation techniques used in salpingectomy: bipolar electric energy versus ultrasound.
The study design is single-center, prospective, before-and-after, with open randomization between two groups defined by coagulation technique.
Who can participate
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Female subjects aged 18
* Scheduled surgery: bilateral laparoscopic salpingectomy associated to hysterectomy for benign indication
Exclusion Criteria:
* Interview revealing disorder entailing unacceptable risk of postoperative complications: coagulation disorder, immune system disorder, evolutive disease, etc.
* Pregnancy, ongoing or planned during the study period
* History of bilateral salpingectomy
* Salpingectomy associated with pelvic cancer
* Oral hormonal contraception during the study period
* Menopause
* Inability to understand information provided
* Not covered by a national health insurance scheme, prisoner or under administrative supervision.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial looked at how removing a fallopian tube (salpingectomy) affects AMH levels, which is a marker of ovarian reserve — can you explain what my own AMH level is right now and whether it puts me at higher or lower risk of losing ovarian reserve if I need a salpingectomy?
2Since this study has been completed, have the results shown a meaningful drop in AMH after salpingectomy, and does that finding change how you'd approach my surgery or recommend any fertility preservation steps beforehand?
3If my fallopian tube needs to be removed, is there a surgical technique that's been shown to better protect the blood supply to my ovary and minimize the impact on my egg supply, based on what studies like this one have found?
4Are there situations where a less complete procedure — like tubal ligation or a partial removal — might be a safer option for preserving my fertility compared to a full salpingectomy, especially given what this research measured?
5If this trial's findings suggest salpingectomy can affect ovarian reserve, should I consider having my AMH tested both before and after any planned surgery so we can track any real changes in my fertility over time?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.